Prognostic markers of disease activity in Hodgkin's disease

被引:6
|
作者
Martinow, AJ [1 ]
Yuen, K [1 ]
Cooper, IA [1 ]
Matthews, JP [1 ]
Juneja, S [1 ]
Wolf, M [1 ]
Januszewicz, H [1 ]
Prince, HM [1 ]
机构
[1] Peter MacCallum Canc Inst, Dept Haematol & Med Oncol, Melbourne, Vic 3000, Australia
关键词
nucleosides; copper; ESR; alkaline phosphatase; Hodgkin's disease;
D O I
10.3109/10428199809068574
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The erythrocyte sedimentation rate (ESR), liver alkaline phosphatase (ALP), serum copper (Cu) and urinary nucleoside excretion (UNs) have been proposed as independent prognostic markers in Hodgkin's Disease (HD). However, their prognostic value has not satisfactorily been directly compared to recognised clinical prognostic factors. One hundred and sixty-eight patients with HD had the above markers performed prior to initial treatment. At a median follow-up of 10.9 yrs, the predicted 10 year relapse free survival(RFS) and overall survival (OS) for the entire cohort is 64% and 66%, respectively. In general, patients with elevated markers were significantly less likely to achieve CR, remain in CR and survive. However, multivariate analysis revealed this was due to the association of elevated markers with stage and constitutional symptoms. Following therapy, elevated markers were also correlated with evidence of clinically detectable disease. We conclude that although UNs, Cu, ALP and ESR reflect disease activity, they do not provide independent information beyond that of clinical assessment.
引用
收藏
页码:383 / 389
页数:7
相关论文
共 50 条
  • [21] Cytogenetic changes in different Hodgkin's disease prognostic groups
    Novik, AA
    Kolubaeva, SN
    Sargevsky, VO
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 397 - 397
  • [22] Prognostic factors in first relapse of Hodgkin's disease.
    Sextro, M
    Welchering, T
    Tesch, H
    Diehl, V
    BLOOD, 1998, 92 (10) : 85A - 85A
  • [23] Prognostic significance of soluble adhesion molecules in Hodgkin's disease
    Syrigos, KN
    Salgami, E
    Karayiannakis, AJ
    Katirtzoglou, N
    Sekara, E
    Roussou, P
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1243 - 1247
  • [24] Prognostic factors for advanced stage Hodgkin's disease (HD)
    Vassilakopoulos, TP
    Barbounis, A
    Angelopoulou, MK
    Boussiotis, VA
    Hatziioannou, M
    Kontopidou, F
    Fessas, P
    Kittas, C
    Pangalis, GA
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 411 - 411
  • [25] Prognostic value of electrophysiological markers in Alzheimer's disease
    Swanwick, GRJ
    Rowan, MJ
    Coen, RF
    Coakley, D
    Lawlor, BA
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 1999, 7 (04): : 335 - 338
  • [26] Hodgkin's Disease - Hodgkin's disease at the end of the XXth century
    Varet, B
    PRESSE MEDICALE, 1997, 26 (23): : 1103 - 1103
  • [27] Prognostic factors in children with Hodgkin disease
    Celkan, Tiraje
    Yildiz, Inci
    PEDIATRIC BLOOD & CANCER, 2008, 51 (05) : 712 - 712
  • [28] Prognostic factors in pediatric Hodgkin disease
    Cindy L. Schwartz
    Current Oncology Reports, 2003, 5 (6) : 498 - 504
  • [29] Prognostic markers in liver disease
    Burdelski, M
    BIOMARKERS OF DISEASE: AN EVIDENCE-BASED APPROACH, 2002, : 221 - 227
  • [30] Hodgkin s disease
    不详
    BRITISH MEDICAL JOURNAL, 1935, 1935 : 323 - 324